NTLA
Price
$11.95
Change
-$0.02 (-0.17%)
Updated
Jul 17, 02:52 PM (EDT)
Capitalization
1.24B
14 days until earnings call
QLGN
Price
$3.27
Change
-$0.66 (-16.79%)
Updated
Jul 17, 02:56 PM (EDT)
Capitalization
6.43M
Interact to see
Advertisement

NTLA vs QLGN

Header iconNTLA vs QLGN Comparison
Open Charts NTLA vs QLGNBanner chart's image
Intellia Therapeutics
Price$11.95
Change-$0.02 (-0.17%)
Volume$3.93K
Capitalization1.24B
Qualigen Therapeutics
Price$3.27
Change-$0.66 (-16.79%)
Volume$680
Capitalization6.43M
NTLA vs QLGN Comparison Chart in %
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. QLGN commentary
Jul 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a StrongBuy and QLGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 17, 2025
Stock price -- (NTLA: $11.96 vs. QLGN: $3.93)
Brand notoriety: NTLA and QLGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 73% vs. QLGN: 4441%
Market capitalization -- NTLA: $1.24B vs. QLGN: $6.43M
NTLA [@Biotechnology] is valued at $1.24B. QLGN’s [@Biotechnology] market capitalization is $6.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $300.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileQLGN’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • QLGN’s FA Score: 1 green, 4 red.
According to our system of comparison, QLGN is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while QLGN’s TA Score has 6 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • QLGN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, QLGN is a better buy in the short-term than NTLA.

Price Growth

NTLA (@Biotechnology) experienced а -1.40% price change this week, while QLGN (@Biotechnology) price change was +11.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.62%. For the same industry, the average monthly price growth was +13.16%, and the average quarterly price growth was +37.94%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

QLGN is expected to report earnings on Jun 30, 2025.

Industries' Descriptions

@Biotechnology (+1.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.24B) has a higher market cap than QLGN($6.43M). NTLA YTD gains are higher at: 2.573 vs. QLGN (-6.651). QLGN has higher annual earnings (EBITDA): -6.73M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. QLGN (388K). QLGN has less debt than NTLA: QLGN (1.43M) vs NTLA (119M). NTLA has higher revenues than QLGN: NTLA (45.6M) vs QLGN (0).
NTLAQLGNNTLA / QLGN
Capitalization1.24B6.43M19,278%
EBITDA-530.8M-6.73M7,886%
Gain YTD2.573-6.651-39%
P/E RatioN/A0.00-
Revenue45.6M0-
Total Cash504M388K129,897%
Total Debt119M1.43M8,298%
FUNDAMENTALS RATINGS
NTLA vs QLGN: Fundamental Ratings
NTLA
QLGN
OUTLOOK RATING
1..100
1741
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3964
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QLGN's Valuation (26) in the null industry is in the same range as NTLA (30) in the Biotechnology industry. This means that QLGN’s stock grew similarly to NTLA’s over the last 12 months.

QLGN's Profit vs Risk Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that QLGN’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as QLGN (100) in the null industry. This means that NTLA’s stock grew similarly to QLGN’s over the last 12 months.

NTLA's Price Growth Rating (39) in the Biotechnology industry is in the same range as QLGN (64) in the null industry. This means that NTLA’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's P/E Growth Rating (44) in the null industry is somewhat better than the same rating for NTLA (100) in the Biotechnology industry. This means that QLGN’s stock grew somewhat faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAQLGN
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 18 days ago
88%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSTSX10.71N/A
N/A
Goldman Sachs Strategic Growth Svc
CBBCX6.44N/A
N/A
AB Relative Value C
AVEEX13.71N/A
N/A
Avantis® Emerging Markets Equity Instl
WCMWX17.84N/A
N/A
WCM Focused Emerging Mkts Ex Chn Inst
USNQX56.39N/A
N/A
Victory NASDAQ-100 Index

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+4.18%
VCYT - NTLA
69%
Closely correlated
-5.55%
CRSP - NTLA
67%
Closely correlated
+4.57%
BEAM - NTLA
65%
Loosely correlated
+2.50%
RXRX - NTLA
57%
Loosely correlated
+3.26%
ABCL - NTLA
56%
Loosely correlated
+3.05%
More

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with VERU. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
+11.33%
VERU - QLGN
34%
Loosely correlated
+3.29%
PHIO - QLGN
32%
Poorly correlated
N/A
ZLDAF - QLGN
29%
Poorly correlated
N/A
NTLA - QLGN
28%
Poorly correlated
+4.18%
MNOV - QLGN
28%
Poorly correlated
-0.81%
More